finance
Finance
Serbia says it has enough fuel reserves as key refinery faces sanctions shutdown
Finance
German motor trade association says EV demand driven 'artificially'
Finance
Poland charges third Ukrainian with helping Russia in railway sabotage
Finance
FTSE 100 edges down with consumer staples, industrials stocks dragging
French PM pressures lawmakers to pass 2026 budget despite parliament tensions
Date: November 24, 2025
PARIS (Reuters) -French Prime Minister Sebastien Lecornu put pressure on lawmakers on Monday to pass the 2026 budget by the end of the year after the deeply divided lower house of parliament rejected...
Novo Nordisk Alzheimer's drug trials fail in blow to weight-loss giant
Date: November 24, 2025
COPENHAGEN (Reuters) -Novo Nordisk said on Monday an older oral version of its semaglutide drug failed to meet its main goal in late-stage trials testing whether the medicine can slow cognitive...
Czech 2026 budget hits snag as election winners reject draft plan
Date: November 24, 2025
PRAGUE (Reuters) -The likely next Czech government rejected the outgoing administration's 2026 budget draft on Monday, raising the chances of a delay to approving the plan by the end of the year and a...
Trafigura's former top nickel trader denies he colluded on $600 million fraud
Date: November 24, 2025
By Eric Onstad LONDON (Reuters) -Trafigura's former head nickel trader denied allegations by Indian businessman Prateek Gupta on Monday in a London trial that he helped devise a $600 million fraud to...
Russia's oil and gas revenue may fall in November by 35%, Reuters calculations show
Date: November 24, 2025
MOSCOW (Reuters) -Russian state oil and gas revenue may fall in November by around 35% from the corresponding month in 2024 to 520 billion roubles ($6.59 billion) due to cheaper oil and a stronger...
Bayer shares up more than 8% on revived fortunes for blood thinner
Date: November 24, 2025
FRANKFURT (Reuters) -Shares in Bayer jumped more than 8% on Monday after initial clinical trial results turned around the fortunes of a key cardiovascular drug that suffered a major development...